Insights to Parkinson’s Disease Models: Evaluating CNTF in Neuroprotection and Disease Progression
Research Article
DOI:
https://doi.org/10.31580/pjmls.v8i1.3241Keywords:
Ciliary neurotrophic factor, CNTF, Neuroprotection, Parkinson’s diseaseAbstract
Parkinson’s Disease (PD) is a progressive neurodegenerative disorder characterized by dopaminergic neuron loss in the substantia nigra, resulting in both motor and non-motor symptoms. Genetic predispositions, oxidative stress, and inflammatory responses contribute significantly to disease progression. This study aimed to investigate the expression of the CNTF gene and evaluate its potential neuroprotective role in Parkinson’s Disease models, correlating gene expression with motor symptom severity and disease progression. A total of 80 individuals were enrolled, including 55 clinically diagnosed PD patients and 25 age-matched healthy controls. Blood samples were collected, and ELISA (CLIA, Chemiluminescence Assay) was used to measure CNTF protein levels. The study revealed a significantly reduced expression of CNTF in PD patients compared to controls (p<0.01). Lower CNTF levels were strongly associated with advanced stages of PD. These findings support a potential role of CNTF in mitigating neuronal loss in PD. Decreased CNTF expression may contribute to neuronal vulnerability in Parkinson’s Disease. CNTF could be a potential biomarker and therapeutic target for slowing disease progression and enhancing neuroprotection.
References
Church FC. Treatment Options for Motor and Non-Motor Symptoms of Parkinson's Disease. Biomolecules. 2021;11(4):612.
Orayj K, Akbari A, Lacey A, Smith M, Pickrell O, Lane EL. Factors affecting the choice of first-line therapy in Parkinson's disease patients in Wales: A population-based study. Saudi Pharm J. 2021;29(2):206-212.
Kwon DK, Kwatra M, Wang J, Ko HS. Levodopa-Induced Dyskinesia in Parkinson's Disease: Pathogenesis and Emerging Treatment Strategies. Cells. 2022;11(23):3736.
Zhang HY, Jiang YC, Li JR, Yan JN, Wang XJ, Shen JB, Ke KF, Gu XS. Neuroprotective effects of insulin-like growth factor-2 in 6-hydroxydopamine-induced cellular and mouse models of Parkinson's disease. Neural Regen Res. 2023;18(5):1099-1106.
Guo H, Chen P, Luo R, Zhang Y, Xu X, Gou X. The Roles of Ciliary Neurotrophic Factor - from Neuronutrition to Energy Metabolism. Protein Pept Lett. 2022;29(10):815-828.
Salmina AB, Kapkaeva MR, Vetchinova AS, Illarioshkin SN. Novel Approaches Used to Examine and Control Neurogenesis in Parkinson's Disease. Int J Mol Sci. 2021;22(17):9608.
Giuliano C, Francavilla M, Ongari G, Petese A, Ghezzi C, Rossini N, Blandini F, Cerri S. Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson's Disease. Int J Mol Sci. 2021;22(16):8920.
Pasquin S, Sharma M, Gauchat JF. Ciliary neurotrophic factor (CNTF): New facets of an old molecule for treating neurodegenerative and metabolic syndrome pathologies. Cytokine Growth Factor Rev. 2015;26(5):507-15.
Sariola H, Sainio K, Arumäe U, Saarma M. Neurotrophins and ciliary neurotrophic factor: their biology and pathology. Ann Med. 1994;26(5):355-63.
Dorszewska J, Kowalska M, Prendecki M, Piekut T, Kozłowska J, Kozubski W. Oxidative stress factors in Parkinson's disease. Neural Regen Res. 2021;16(7):1383-1391.
Costa HN, Esteves AR, Empadinhas N, Cardoso SM. Parkinson's Disease: A Multisystem Disorder. Neurosci Bull. 2023;39(1):113-124.
Lübke JH, Idoon F, Mohasel-Roodi M, Alipour F, Hami J, Ehteshampour A, Mostafaee H, Sadeghi A. Neurotrophic factors in Alzheimer's disease: pathogenesis and therapy. Acta Neurobiol Exp (Wars). 2021;81(4):314-327.
Lindholm P, Saarma M. Cerebral dopamine neurotrophic factor protects and repairs dopamine neurons by novel mechanism. Mol Psychiatry. 2022;27(3):1310-1321.
Liu GQ, Liu ZX, Lin ZX, Chen P, Yan YC, Lin QR, Hu YJ, Jiang N, Yu B. Effects of Dopamine on stem cells and its potential roles in the treatment of inflammatory disorders: a narrative review. Stem Cell Res Ther. 2023;14(1):230.
Stefani A, Pierantozzi M, Cardarelli S, Stefani L, Cerroni R, Conti M, Garasto E, Mercuri NB, Marini C, Sucapane P. Neurotrophins as Therapeutic Agents for Parkinson's Disease; New Chances From Focused Ultrasound? Front Neurosci. 2022;16:846681.
Kathanadan Chackochan B, Johnson S, Thameemul Ansari HJ, Vengellur A, Sivan U, Koyyappurath S, P S BC. Transcriptomic analysis of CNTF-treated mouse subventricular zone-derived neurosphere culture reveals key transcription factor genes related to adult neurogenesis. Heliyon. 2024;10(19):e38496.
Palasz E, Wilkaniec A, Stanaszek L, Andrzejewska A, Adamczyk A. Glia-Neurotrophic Factor Relationships: Possible Role in Pathobiology of Neuroinflammation-Related Brain Disorders. Int J Mol Sci. 2023;24(7):6321.
Morrone Parfitt G, Coccia E, Goldman C, Whitney K, Reyes R, Sarrafha L, Nam KH, Sohail S, Jones DR, Crary JF, Ordureau A, Blanchard J, Ahfeldt T. Disruption of lysosomal proteolysis in astrocytes facilitates midbrain organoid proteostasis failure in an early-onset Parkinson's disease model. Nat Commun. 2024;15(1):447.
Han L, Chen W, Zong Y, Zhao Y, Li J, He Z, Du R. Analysis of the mechanism of fibrauretine alleviating Alzheimer's disease based on transcriptomics and proteomics. Korean J Physiol Pharmacol. 2024;28(4):361-377.
Sundram S, Dhiman N, Malviya R, Awasthi R. Non-coding RNAs in Regulation of Protein Aggregation and Clearance Pathways: Current Perspectives Towards Alzheimer's Research and Therapy. Curr Gene Ther. 2024;24(1):8-16.
Kumari S, Kamiya A, Karnik SS, Rohilla S, Dubey SK, Taliyan R. Novel Gene Therapy Approaches for Targeting Neurodegenerative Disorders: Focusing on Delivering Neurotrophic Genes. Mol Neurobiol. 2025;62(1):386-411.
Lutfi Ismaeel G, Makki AlHassani OJ, S Alazragi R, Hussein Ahmed A, H Mohamed A, Yasir Jasim N, Hassan Shari F, Almashhadani HA. Genetically engineered neural stem cells (NSCs) therapy for neurological diseases; state-of-the-art. Biotechnol Prog. 2023;39(5):e3363.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Pak-Euro Journal of Medical and Life Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
